NeuroMab™ Anti-Amyloid Beta BBB Shuttle Antibody(NRZP-1022-ZP4049)

Figure 1 Binding properties of the fusion protein to the Aβ structure.

Figure 2 Plaque decoration of anti-Aβ monoclonal antibody mAb31.

Figure 3 shows the quantification of the dual Fab-mAb31 construct.

Figure 4 shows the quantification of individual Fab-mAb31 constructs.

Figure 5 Plaque decoration of two different doses of anti-Aβ monoclonal antibody mAb31 and a very low dose of single Fab mAb31 (single Fab fused to the C-terminus of mAb31)

Figure 6 Quantitative expression of TfR cells treated with single Fab-mab31 or double Fab-mAb31

Figure 7 In vivo cellular trafficking of TfR treated with single Fab-mab31 or double Fab-mAb31.

Figure 8 In vivo cellular trafficking of TfR treated with single Fab-mab31 or double Fab-mAb31.

Figure 9 Antibody multimers with TfR scFab fragments fused to the Fc C-terminus do not induce ADCC.

Figure 10 Quantitative morphological analysis of plaque immunohistochemical staining showing cortex and hippocampus.

Figure 11 demonstrates that a low dose of the sFab construct (2.66 mg/kg) reached plaques in the brain rapidly and significantly compared to mAb31 at 2 mg/kg and 10 mg/kg.

Figure 12 In vivo cellular trafficking of TfR treated with double Fab-mab31.

Figure 13 In vivo cellular trafficking of TfR treated with a single Fab-mab31.